These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18173953)

  • 1. Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?
    Nicholls SJ; Tuzcu EM; Nissen SE
    Curr Atheroscler Rep; 2007 Oct; 9(4):266-73. PubMed ID: 18173953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.
    Rosenson RS; Brewer HB; Ansell B; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR
    Circulation; 2013 Sep; 128(11):1256-67. PubMed ID: 24019446
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction.
    Tornvall P; Karpe F; Carlson LA; Hamsten A
    Atherosclerosis; 1991 Sep; 90(1):67-80. PubMed ID: 1799399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.
    Marcovina S; Packard CJ
    J Intern Med; 2006 May; 259(5):437-46. PubMed ID: 16629849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels.
    Leroux G; Lemieux I; Lamarche B; Cantin B; Dagenais GR; Lupien PJ; Després JP
    Metabolism; 2000 Jan; 49(1):53-61. PubMed ID: 10647064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
    Xu RX; Guo YL; Li XL; Li S; Li JJ
    Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):475-81. PubMed ID: 24739131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher level of plasma cholesteryl ester transfer activity from high-density lipoprotein to apo B-containing lipoproteins in subjects with angiographically detectable coronary artery disease.
    Hibino T; Sakuma N; Sato T
    Clin Cardiol; 1996 Jun; 19(6):483-6. PubMed ID: 8790953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
    Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoproteins and the endothelium: past, present and future.
    Lee J; Leeson PC
    Hellenic J Cardiol; 2006; 47(3):158-9. PubMed ID: 16862823
    [No Abstract]   [Full Text] [Related]  

  • 10. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
    Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
    Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
    J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events.
    Phillips NR; Waters D; Havel RJ
    Circulation; 1993 Dec; 88(6):2762-70. PubMed ID: 8252689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Density Lipoprotein Is Associated with Progression of Intracranial Aneurysms.
    Huang Q; Shang-Guan HC; Wu SY; Yao PS; Sun Y; Zeng YL; Zheng SF; Chen GR; Lin YX; Kang DZ
    World Neurosurg; 2018 Dec; 120():e234-e240. PubMed ID: 30121407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients.
    Rolla R; De Mauri A; Valsesia A; Vidali M; Chiarinotti D; Bellomo G
    J Nephrol; 2015 Dec; 28(6):749-55. PubMed ID: 25971848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoproteins and apolipoproteins in the young and familial risk of coronary atherosclerosis.
    Uiterwaal CS; Witteman JC; van Stiphout WA; Krauss XH; de Bruijn AM; Hofman A; Grobbee DE
    Atherosclerosis; 1996 May; 122(2):235-44. PubMed ID: 8769686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.
    Sharrett AR; Ballantyne CM; Coady SA; Heiss G; Sorlie PD; Catellier D; Patsch W;
    Circulation; 2001 Sep; 104(10):1108-13. PubMed ID: 11535564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.